An optimized approach to study endocannabinoid signaling: Evidence against constitutive activity of rat brain adenosine A 1 and cannabinoid CB 1 receptors

British Journal of Pharmacology

Volumn 140, Issue 8, 2003, Pages 1451-1459

  Savinainen, Juha R ^a   Saario, Susanna M ^a   Niemi, Riku ^a   Järvinen, Tomi ^a   Laitinen, Jarmo T ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Adenosine A1 receptor; AM251; Constitutive activity; Cryptic adenosine; Endocannabinoid; Inverse agonist; Monoacylglycerol lipase; SR141716

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE DEAMINASE; CAFFEINE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CIRSIMARITIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); METHYL GROUP; METHYLARACHIDONOYLFLUOROPHOSPHONATE; N 0840; PHOSPHONIC ACID DERIVATIVE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; BRAIN MEMBRANE; CEREBELLUM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; ENZYME DEGRADATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOPHILICITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SIGNAL NOISE RATIO; SIGNAL TRANSDUCTION; TECHNIQUE;

ADENOSINE DEAMINASE; ANIMALS; ARACHIDONIC ACIDS; CEREBELLUM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MALE; PHOSPHONIC ACIDS; PIPERIDINES; PYRAZOLES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A1; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION;

EID: 0346057814     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705577     Document Type: Article

References (34)

1. BASS, C.E., GRIFFIN, G., GRIER, M., MAHADEVAN, A., RAZDAN, R.K. & MARTIN, B.R. (2002). SR-141716A-induced stimulation of locomotor activity A structure-activity relationship study. Pharmacol. Biochem. Behav., 74, 31-40.
2. BISOGNO, T., MELCK, D., DE PETROCELLIS, L., BOBROV, M.Y., GRETSKAYA, N.M., BEZUGLOV, V.V., SITACHITTA, N., GERWICK, W.H. & DI MARZO, V. (1998). Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun., 248, 515-522.
3. BREIVOGEL, C.S., GRIFFIN, G., DI MARZO, V. & MARTIN, B.R. (2001). Evidence for a new G-protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol., 60, 155-163.
4. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J. Biol. Chem., 273, 16865-16873.
5. DEUTSCH, D.G., OMEIR, R., ARREAZA, G., SALEHANI, D., PRESTWICH, G.D., HUANG, Z. & HOWLETT, A. (1997). Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem. Pharmacol., 53, 255-260.
6. DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
7. DINH, T.P., CARPENTER, D., LESLIE, P.M., FREUND, T.F., KATONA, I., SENSI, S.L., KATHURIA, S. & PIOMELLI, D. (2002a). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA., 99, 10819-10824.
8. DINH, T.P., FREUND, T.F. & PIOMELLI, D. (2002b). A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem. Phys. Lipids, 121, 149-158.
9. FERNANDO, S.R. & PERTWEE, R.G. (1997). Evidence that methyl arachidonyl fluorophosphonate is an irreversible cannabinoid receptor antagonist. Br. J. Pharmacol., 121, 1716-1720.
10. GOPARAJU, S.K., UEDA, N., TANIGUCHI, K. & YAMAMOTO, S. (1999). Enzymes of porcine brain hydrolysing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem. Pharmacol., 57, 417-423.
11. 35S]thio)-triphosphate binding assay in rat cerebellar membranes. J. Pharmacol. Exp. Ther., 285, 553-560.
12. 1 receptor. Proc. Natl. Acad. Sci. USA., 98, 3662-3665.
13. HURST, D.P., LYNCH, D.L., BARNETT-NORRIS, J., HYATT, S.M., SELTZMAN, H.H., ZHONG, M., SONG, Z.-H., NIE, J., LEWIS, D. & REGGIO, P.H. (2002). N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-lH- pyrazole-3-carboxamide (SRI 41716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol. Pharmacol., 62, 1274-1287.
14. KOUTEK, B., PRESTWICH, G.D., HOWLETT, A.C., CHIN, S.A., SALEHANI, D., AKHAVAN, N. & DEUTSCH, D.G. (1994). Inhibitors of arachidonoyl ethanolamide hydrolysis. J. Biol. Chem., 269, 22937-22940.
15. 35S]guanosine 5′(γ-thio)triphosphate autoradiography. Neuroscience, 90, 1265-1279.
16. 3 receptor-dependent G-protein activation in rat brain tissue sections. J. Neurochem., 71, 808-816.
17. LAN. R., LIU, Q., FAN, P., LIN, S., FERNANDO, S.R., MCCALLION, D.. PERTWEE, R. & MAKRIYANNIS, A. (1999). Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem., 42, 769-776.
18. 1 receptor. Eur. J. Pharmacol., 334, R1-R2.
19. MATO, S., PAZOS, A. & VALDIZÁN, E.M. (2002). Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain. Eur. J. Pharmacol., 443, 43-46.
20. MECHOULAM, R., BEN-SHABAT, S., HANUS, L., LIGUMSKY, M., KAMINSKI, N.E., SCHATZ, A.R., GOPHER, A., ALMOG, S., MARTIN, B.R., COMPTON, D.R., PERTWEE, R.G., GRIFFIN, G., BAYEWHICH, M., BARG, J. & VOGEL, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine cut, that binds to cannabinoid receptors. Biochem. Pharmacol., 50, 83-90.
21. 35S]GTPgammaS binding in brain modulation by endogenous adenosine. Neuropharmacology, 39, 282-289.
22. NIE, J. & LEWIS, D.L. (2001). Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration. J. Neurosci., 21, 8758-8764.
23. 1 cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling. J. Med. Chem., 45, 1748-1756.
24. 1 adenosine receptors: occupation of cryptic binding sites by endogenous vesicular adenosine. Mol. Pharmacol., 42, 765-772.
25. RINALDI-CARMONA, M., BARTH, F., HEAULME, M., ALONSO, R., SHIRE, D., CONGY, C., SOUBRIE, P., BRELIERE, J.C. & LE FUR, G. (1995). Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci., 56, 1941-1947.
26. RINALDI-CARMONA, M., BARTH, F., HEAULME, M., SHIRE, D., CALANDRA, B., CONGY, C., MARTINEZ, S., MARUANI, J., NELIAT, G., CAPUT, D., FERRARA, P., SOUBRIE, P., BRELIERE, J.C. & LE FUR, G. (1994). SR141716A. a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 350, 240-244.
27. RINALDI-CARMONA, M., BARTH, F., MILLAN, J., DEROCQ, J.-M., CASELLAS, P., CONGY, C. OUSTRIC, D., SARRAN, M., BOUABOULA, M., CALANDRA, B., PORTIER, M., SHIRE, D., BRELIERE, J.-C. & LE FUR, G. (1998). SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 284, 644-650.
28. 3 receptors. Br. J. Pharmacol., 135, 383-392.
29. SAVINAINEN, J.R., JÄRVlNEN, T., LAINE, K. & LAITINEN, J.T. (2001). Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB1 receptor-dependent G-protein activation in rat cerebellar membranes. Br. J. Pharmacol., 134, 664-672.
30. SEIFERT, R. & WENZEL-SEIFERT, K. (2002). Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 366, 381-416.
31. SHRYOCK, J.C., OZECK, M.J. & BELARDINELLI, L. (1998). Inverse agonists and neutral antagonists of recombinant human A1 adenosine receptors stably expressed in Chinese hamster ovary cells. Mol. Pharmacol., 53, 886-893.
32. SIM-SELLEY, L.J., BRUNK, L.K. & SELLEY, D.E. (2001). Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur. J. Pharmacol., 414, 135-143.
33. SUGIURA, T., KONDO, S., SUKAGAWA, A., NAKANE, S., SHINODA, A., ITOH, K., YAMASHITA, A. & WAKU, K. (1995). 2-arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun., 215, 89-97.
34. UEDA, N. (2002). Endocannabinoid hydrolases. Prostag. Oth. Lipid M., 68-69, 521-534.